DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



5HT3 Antagonism and Auditory Gating in Schizophrenia

Information source: Department of Veterans Affairs
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Schizophrenia

Intervention: ondansetron (Drug); neuropsychological testing (Behavioral); nicotine (Drug); haloperidol (Drug)

Phase: N/A

Status: Completed

Sponsored by: Department of Veterans Affairs

Summary

The target groups in this study are brain waves and neurotransmitters (chemical messengers) in the brain. Subjects with diagnosed with schizophrenia will be studied. The study will help understand more about normal brain functioning and how that functioning differs in people with schizophrenia. Another purpose of this study is to determine how the altered brain functioning in schizophrenia contributes the symptoms found in the illness.

Clinical Details

Official title: 5HT3 Antagonism and Auditory Gating in Schizophrenia

Study design: Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Eligibility

Minimum age: 18 Years. Maximum age: 55 Years. Gender(s): Both.

Criteria:

Subjects with diagnosed with schizophrenia will be studied.

Locations and Contacts

VAMC, Denver, Colorado 80013, United States
Additional Information

Starting date: June 1998
Last updated: January 20, 2009

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015